In this preprint, researchers tested Human Platelet Lysate (HPL) as a fetal bovine serum (FBS) alternative for differentiating human induced pluripotent stem cells into vascular mural cells under clinically compliant conditions. Just 1% HPL performed comparably to 10% FBS for mural cell differentiation, while the HPL concentration used strongly influenced the resulting cell fate.
PL BioScience and ELAREM™ products were not specifically tested in this work. Its relevance lies in what it shows for HPL in general: as an FBS alternative in stem cell differentiation, the concentration of HPL matters as much as the choice of supplement.
